AI-generated summary
The authors retrospectively reviewed 10 consecutive patients with vitiligo treated with the JAK 1/3 inhibitor tofacitinib. Five patients achieved some repigmentation, at sites of sunlight exposure or low-dose narrowband UVB phototherapy, and the authors suggest light exposure may be needed for melanocyte regeneration. The study was small, retrospective and had no control group.
- Participants
- 10
- Who or what was studied
- Ten consecutive patients with vitiligo treated with tofacitinib
- Limits stated in the abstract
- The abstract states the small study population, retrospective design and lack of a control group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Phototherapy, Control group, Ultraviolet, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.